Previous 10 | Next 10 |
2023-03-06 07:13:32 ET Armata Pharmaceuticals ( NYSE: ARMP ) said its inhaled bacterial infection drug for lung disorder was well-tolerated with a treatment emergent adverse event (TEAE) profile similar to placebo in a phase 1b/2a trial. The study, dubbed SWARM-P.a., ev...
Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis PR Newswire AP-PA02 is well-tolerated and data supports progression to Phase 2b Also announces first subject dosed ...
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC PR Newswire MARINA DEL REY, Calif. , Jan. 10, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" ...
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection PR Newswire MARINA DEL REY, Calif. , Dec. 22, 2022 /PRNewswire/ -- Armata...
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage PR Newswire MARINA DEL REY, Calif. , Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company")...
Armata Pharmaceuticals press release ( NYSE: ARMP ): Q3 GAAP EPS of -$0.24 beats by $0.04 . Revenue of $1.34M (+7.2% Y/Y) misses by $0.32M . For further details see: Armata Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04, revenue of $1.34M misses by $0....
Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update PR Newswire MARINA DEL REY, Calif. , Nov. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology co...
Armata Pharmaceuticals press release ( NYSE: ARMP ): Q2 GAAP EPS of -$0.26. Revenue of $1.88M (+60.7% Y/Y). For further details see: Armata Pharmaceuticals GAAP EPS of -$0.26, revenue of $1.88M
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update PR Newswire MARINA DEL REY, Calif. , Aug. 11, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology c...
Armata Pharmaceuticals ( NYSE: ARMP ) on Monday said the U.S. Food and Drug Administration (FDA) had cleared the company's investigational new drug (IND) application for its AP-SA02 treatment for prosthetic joint infection. Prosthetic joint infection is a serious compl...
News, Short Squeeze, Breakout and More Instantly...
Armata Pharmaceuticals Inc. Company Name:
ARMP Stock Symbol:
NYSE Market:
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update PR Newswire LOS ANGELES , May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology com...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 20...